The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat has raised hope of an important new treatment option for people who struggle to control their blood pressure with current therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback